Previous 10 | Next 10 |
Austin, TX, Oct. 26, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam ® ), for the treatment of bone cancer and related diseases and conditions, today ann...
Glioblastoma is a deadly and aggressive type of cancer that develops in an individual’s brain or spinal cord. This fatal cancer, which has a 15-month median survival time, claims the lives of more than 10,000 Americans annually. Treatment for brain tumors usually... Read more &...
Two studies recently conducted by Cedars-Sinai Cancer scientists have discovered new information that may improve the understanding of why some patients don’t respond to treatment and what drives ovarian cancer development. Epithelial ovarian cancer is the most common ovarian cancer...
A new report has highlighted that the rate of death due to cancer in America has steadily declined in the last few decades. As of January 2022, more than 18 million individuals who have survived cancer live in America. This is a new record, especially if one compares the figures against th...
New research has found that antibiotics may speed up melanoma growth in bones by weakening the body’s immune response and obstructing microbiome in the gut. Melanoma is an aggressive cancer of the skin that often spreads to a person’s bones. Once this cancer metastasizes, a...
QSAM Biosciences (OTCQB: QSAM) is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “With the overall incidence of chil...
A recently published report has found that prevention strategies, diagnostic tools and exceptional strides in cancer treatments have driven down cancer mortality rates. The report, which was published by the American Association for Cancer Research, highlighted that over the last 20 years,...
Scientists have for the longest time believed that cancer begins to develop when cells in the body acquire more mutations and multiply at an abnormal rate. However, new research has shed light on how air pollution can cause cancer, a discovery that could completely change the understanding...
Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organization QSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient popul...
Osteosarcoma is a rare bone cancer that most often affects the long bones in the legs and arms. Although it occurs most often in young adults, older adults and younger children are also at risk of developing osteosarcoma . This type of bone cancer is often characterized by bone pain and...
News, Short Squeeze, Breakout and More Instantly...
QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc . (OTCQB: QSAM) (“ QSAM ” or the “ Company ”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par...
QSAM Biosciences (OTCQB: QSAM) , a clinical-stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has signed a definitive agreement and plan of merger pr...